The public defence will be held as a video conference over Zoom.
The defence will follow regular procedure as far as possible, hence it will be open to the public and the audience can ask ex auditorio questions when invited to do so.
Click here to participate in the public defence
Due to copyright reasons, an electronic copy of the thesis must be ordered from the faculty. In order for the faculty to have time to process the order, it must be received by the faculty no later than 2 days prior to the public defence. Orders received later than 2 days before the defence will not be processed. Inquiries regarding the thesis after the public defence must be addressed to the candidate.
Digital Trial Lecture - time and place
Adjudication committee
- First opponent: Clinical Professor Torben Lykke Sørensen, University of Copenhagen, Denmark
- Second opponent: Professor Madeleine Zetterberg, University of Gothenburg, Sweden
- Third member and chair of the evaluation committee: Professor John-Anker Zwart, Institute of Clinical Medicine, University of Oslo
Chair of defence
Associate Professor Elisabeth Qvigstad, Institute of Clinical Medicine, University of Oslo
Principal supervisor
Professor II Morten C. Moe, Institute of Clinical Medicine, University of Oslo
Summary
Neovascular age-related macular degeneration (nAMD) is causing a progressive central vision loss. Intravitreal anti–vascular endothelial growth factor (anti-VEGF) treatment is often effective, but requires frequent injections for years. Knowledge about what is important according to nAMD patients requiring frequent injections is limited. In this project, we aimed to explore patient-reported outcome measures (PROM) during treatment of nAMD. We identified the most important dimensions during treatment according to patients and developed a new PROM, Dimensions of importance in treatment of nAMD (DITAMD). We found that patients, in general were satisfied with their treatment. However, five key-areas of improvement were identified including preserving vision, pain relief, early access to treatment, information about the diagnosis and treatment as well visual aids. We further followed 197 patients during the first year of treatment. There were significant improvements in visual acuity, self-reported visual function and symptom state. However, these results were depending on whether therapy was given to the best or worst seeing eye. If only the worst seeing eye was treated, there was no significant change in patient-reported visual function despite a significant improvement in visual acuity.
Additional information
contact the research support staff